Drug Profile

RDX 002 - Response Pharmaceuticals

Alternative Names: RDX-002; RDX002-Response Pharmaceuticals

Latest Information Update: 12 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sanofi
Developer Response Pharmaceuticals
Class Small molecules
Mechanism of Action Microsomal triglyceride transfer protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Weight gain

Most Recent Events

06 Feb 2025 Response Pharmaceuticals completes enrolment in its phase II trial for Obesity in USA
27 Sep 2024 Phase-II clinical trials in Weight gain in USA (unspecified route) (NCT06640972)
28 Aug 2024 Response Pharmaceuticals plans a phase-II trial for Obesity in Q3 2024 (PO), (RDX-002-024-011) (Response Pharmaceuticals pipeline, August 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com